HCM 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
HCM 近期報酬表現
-2.74%
Hutchmed (china) ltd
2.35%
同產業平均
-0.21%
S&P500
與 HCM 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
ZLAB | Zai lab ltd | 3 分 | 4 分 | 2 分 | 3 分 | 1 分 | |
BGNE | Beigene ltd | 4 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
NTLA | Intellia therapeutics inc | 5 分 | 3 分 | 4 分 | 3 分 | 1 分 | |
KYMR | Kymera therapeutics inc | 3 分 | 4 分 | 2 分 | 3 分 | 1 分 | |
ADPT | Adaptive biotechnologies corp | 4 分 | 4 分 | 3 分 | 3 分 | 1 分 |
- ZLAB Zai lab ltd價值 3 分趨勢 4 分波段 2 分籌碼 3 分股利 1 分查看更多
HCM 公司資訊
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.